KRAS and familial pancreatic carcinoma: After that, whole-genome sequencing [16], integrated genomic and transcriptomc analysis [17], including efforts from TCGA network [18] validate the KRAS, TP53 mutations and CDKN2A, SMAD copy number alterations in pancreatic cancer.